Holen Sie sich die Stockscreener-App
213.29
0.02%
0.05
Handel nachbörslich:
213.30
0.01
+0.00%
Schlusskurs vom Vortag:
$213.24
Offen:
$212.84
24-Stunden-Volumen:
343.34K
Relative Volume:
0.60
Marktkapitalisierung:
$13.03B
Einnahmen:
$534.57M
Nettoeinkommen (Verlust:
$-293.67M
KGV:
-42.93
EPS:
-4.968
Netto-Cashflow:
$-187.10M
1W Leistung:
+2.06%
1M Leistung:
+5.51%
6M Leistung:
+23.22%
1J Leistung:
+54.56%
1-Tages-Spanne:
$210.76
$215.98
1-Wochen-Bereich:
$207.28
$215.98
52-Wochen-Spanne:
$118.03
$229.94
Ascendis Pharma A S Adr Stock (ASND) Company Profile
Firmenname
Ascendis Pharma A S Adr
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie ASND mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ASND
Ascendis Pharma A S Adr
|
213.29 | 13.03B | 534.57M | -293.67M | -187.10M | -4.968 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Ascendis Pharma A S Adr Stock (ASND) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-18 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-10-17 | Eingeleitet | Raymond James | Strong Buy |
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-05-05 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-04-16 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-01-07 | Eingeleitet | UBS | Buy |
| 2024-09-05 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2024-06-25 | Hochstufung | TD Cowen | Hold → Buy |
| 2024-05-31 | Eingeleitet | Stifel | Buy |
| 2023-12-20 | Eingeleitet | Jefferies | Buy |
| 2023-06-14 | Fortgesetzt | Credit Suisse | Neutral |
| 2023-04-05 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-04-04 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-03 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-10-20 | Eingeleitet | Goldman | Buy |
| 2022-08-30 | Fortgesetzt | Berenberg | Buy |
| 2022-03-28 | Fortgesetzt | Wedbush | Outperform |
| 2022-03-15 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-03-01 | Eingeleitet | Citigroup | Buy |
| 2022-02-14 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2022-01-06 | Eingeleitet | Cowen | Market Perform |
| 2021-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2021-10-20 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-03-30 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-03-11 | Fortgesetzt | Stifel | Buy |
| 2020-12-17 | Eingeleitet | Berenberg | Buy |
| 2020-09-14 | Fortgesetzt | JP Morgan | Overweight |
| 2020-03-20 | Eingeleitet | Oppenheimer | Outperform |
| 2019-10-11 | Eingeleitet | Morgan Stanley | Overweight |
| 2019-03-25 | Eingeleitet | Evercore ISI | Outperform |
| 2019-01-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-01-24 | Hochstufung | Leerink Partners | Mkt Perform → Outperform |
| 2018-06-26 | Eingeleitet | Stifel | Buy |
| 2018-04-02 | Bestätigt | Leerink Partners | Mkt Perform |
| 2017-05-11 | Eingeleitet | JP Morgan | Overweight |
| 2017-03-09 | Herabstufung | Leerink Partners | Outperform → Mkt Perform |
| 2017-02-09 | Eingeleitet | Credit Suisse | Outperform |
| 2016-09-26 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Ascendis Pharma A S Adr Aktie (ASND) Neueste Nachrichten
Ascendis Pharma ADR reaches 80-plus relative strength rating benchmark - MSN
Ascendis Pharma ADR Reaches 80-Plus Relative Strength Rating Benchmark - Investor's Business Daily
Here's How Much $1000 Invested In Ascendis Pharma 10 Years Ago Would Be Worth Today - Sahm
Ascendis Pharma’s Price Surge Amid New Developments - StocksToTrade
Looking Into Ascendis Pharma AS's Recent Short Interest - Sahm
Taking on analysts’ expectations and winning: Ascendis Pharma A/S ADR (ASND) - setenews.com
Monolithic Power, Ascendis Pharma And More: CNBC's 'Final Trades' - Sahm
The time has not yet come to remove your chips from the table: Ascendis Pharma A/S ADR (ASND) - setenews.com
Honda Upgraded, McDonald’s Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Ascendis Pharma Hit By FDA Delay As TransCon CNP Decision Slips To 2026 - Sahm
Ascendis Pharma Reports Third Quarter 2025 Financial Results - Sahm
Is the Market Bullish or Bearish on Ascendis Pharma AS? - Sahm
Ascendis Announces Extension of FDA Review Period for TransCon CNP (navepegritide) for Children with Achondroplasia - GlobeNewswire Inc.
Ascendis Announces Extension of FDA Review Period for TransCon CNP (navepegritide) for Children with Achondroplasia - Sahm
Ascendis Pharma ADR Clears Technical Benchmark, Hitting 90-Plus RS Rating - MSN
ASND | Ascendis Pharma A/S ADR SEC Filings - MarketWatch
European ADRs Slip As Gains And Losses Balance Out - Finimize
Take off with Ascendis Pharma A/S ADR (ASND): Get ready for trading - Setenews
Breakthrough And Pullback | 5 Stocks Deserve Close Attention: ASND, IDCC And More - Sahm
Ascendis Pharma Likely To Report Narrower Q3 Loss; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call - Sahm
Are These 4 Biotech Stocks Set to Beat Q3 Earnings Estimates? - TradingView
Apple Upgraded, DraftKings Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Stocks Showing Rising Market Leadership: Ascendis Pharma ADR Earns 81 RS Rating - MSN
New Pooled 3-Year Analysis Confirms Sustained, Clinically Meaningful Improvements in Renal Function for TransCon® PTH (Palopegteriparatide)-Treated Adults with Hypoparathyroidism - Sahm
Should Positive Three-Year TransCon PTH Data Prompt Action From Ascendis Pharma (ASND) Investors? - Sahm
Ascendis Pharma to Report Third Quarter 2025 Financial Results and Provide Business Update on November 12, 2025 - Sahm
3-Year Renal Data in Adults with Hypoparathyroidism Treated with TransCon® PTH (Palopegteriparatide) to Be Shared at Kidney Week 2025 - Sahm
Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years - Sahm
eBay Upgraded, Meta Platforms Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Ascendis Pharma (NasdaqGS:ASND): Evaluating Valuation as Analyst Confidence Rises on Key EMA Filing - Sahm
How Ascendis Pharma’s (ASND) TransCon CNP EMA Submission Has Shaped Its Rare Disease Investment Story - Sahm
Should Investors Consider Ascendis Pharma After FDA Nod for Next-Gen Hormone Therapy in 2025? - Sahm
Raymond James initiates Ascendis Pharma stock with Strong Buy rating - Investing.com
Ascendis Pharma A/S Sponsored ADR (ASND) Stock Price Today | Live Chart & News - Traders Union
Brokerages Set Ascendis Pharma A/S (NASDAQ:ASND) Target Price at $244.64 - Defense World
Walt Disney Upgraded, Southwest Airlines Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Book value per share of Ascendis Pharma A/S Sponsored ADR – MUN:A71 - TradingView
Ascendis Pharma (ASND) Is Up 6.9% After EMA Filing for TransCon CNP in Achondroplasia Treatment - Sahm
Ascendis Submits Marketing Authorisation Application to the European Medicines Agency for TransCon® CNP for Treatment of Children with Achondroplasia - Sahm
Does Analyst Backing of Yorvipath Shift the Competitive Narrative for Ascendis Pharma (ASND)? - Sahm
Ascendis Pharma increases share capital following warrant exercises - Investing.com
Earnings call transcript: Ascendis Pharma Q2 2025 beats EPS forecasts - Investing.com
Ascendis Pharma A/S Q2 Earnings Call Highlights Growth - The Globe and Mail
Stocks To Watch: Sociedad Quimica ADR Sees Relative Strength Rating Rise To 80 - inkl
Biotech Stocks To Watch And Pharma Industry News - Investor's Business Daily
Stocks To Watch: Ascendis Pharma ADR Sees RS Rating Rise To 92 - Investor's Business Daily
Ascendis Pharma AS earnings beat by €0.45, revenue topped estimates - Investing.com
Ascendis Pharma stock rating reiterated by Cantor Fitzgerald ahead of Q2 results - Investing.com
Ascendis Pharma ADR Shows Rising Price Performance With Jump To 81 RS Rating - Investor's Business Daily
Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND), BioNTech SE (BNTX) and Galapagos (GLPG) - The Globe and Mail
Ascendis Pharma stock jumps after FDA approves SKYTROFA for adult GHD - Investing.com
Finanzdaten der Ascendis Pharma A S Adr-Aktie (ASND)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.57%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):